ANDHealth News

Supported by the Medical Research Future Fund (MRFF), ANDHealth+ is the flagship program of ANDHealth, one of Australia’s leading digital and connected health commercialisation organisations. Applications for the first new intake of ANDHealth+ are now open to companies seeking to join a select group of past and present ANDHealth+ portfolio companies, which to date have raised over $187 million in follow-on funding, generated more than $77 million in revenues, created over 500 new jobs and impacted more than 2.9 million patients.

ANDHealth+ is a non-equity-taking accelerator and incubation program that connects digital and connected health startups with expert support and tranched, non-dilutive funding to address critical commercialisation hurdles.

According to an independent assessment, ANDHealth+ companies raise $19.70 in follow-on financing for every dollar invested through the ANDHealth+ program. Companies selected for ANDHealth+ raise up to 13 times more follow-on funding and generate up to 2.9 times more revenue than companies participating in other leading accelerator programs across technology and health.

“The impact demonstrated by the ANDHealth+ program to date shows that Australia can truly build world-class digital and connected health technologies, products and services,” said ANDHealth Chief Executive Bronwyn Le Grice.

“This program creates fit-to-fund and fit-to-deploy technologies at the forefront of health innovation and we look forward to working with the Australian Government to increase the uptake of these technologies within the Australian healthcare system.

“Australia’s digital and connected health technology sector has been growing more than 55 per cent year-on-year, which is nothing short of remarkable. The sector is poised to deliver substantive economic and health benefits to the Australian economy, which is why it’s absolutely vital for the government to continue to support their commercialisation through grants like the MRFF Commercialisation Initiative.”

“The new companies selected in this new intake will build on the success of the 28 companies that have participated in the ANDHealth+ program to date. This includes companies such as the trailblazing Australian medical device company, Baymatob, who created a world-first, AI-guided wearable sensor platform that monitors pregnancy and labour to predict the risk of postpartum haemorrhage before it happens, and Atmo Biosciences, who created a world-first, vitamin-sized swallowable sensor capsule to detect gut biomarkers.”

In addition to up to $5 million in flexible, milestone-based non-dilutive funding, recipients will receive access to a global network of industry advisors, investors, clinicians, executives and corporate partners over a two-year, two-stage program.

Successful applicants will also receive highly skilled, hands-on project management and support services, leading them to become technically and commercially de-risked and globally connected. There are also no equity or intellectual property transfer requirements from being involved in the program.

ANDHealth+ has a significant history of driving successful commercialisation and impact, operating since 2017 and having been supported through the MRFF and Department of Health since 2022. An independent economic assessment conducted by consulting firm L.E.K. in 2024 revealed that ANDHealth+ outperformed leading Australian accelerators across the health and technology sectors with between 2.5 to 13 times more follow-on funding raised, 1.6 to 4.7 times more jobs created and 2.2 to 2.9 times more revenue earned.

In July, it was announced that ANDHealth was one of three organisations selected to share in nearly $100 million in funding to uplift SMEs with promising medical innovations to be commercialised by and for Australians. ANDHealth is the first of the three to open applications for its incubator program.

Applications for ANDHealth+ intake one will close at 11:59 pm (AEDT) on 16 January 2026.